

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 February 2023 (09.02.2023)



(10) International Publication Number
WO 2023/012233 A1

(51) International Patent Classification:
A61K 31/4535 (2006.01) *A61P 31/14* (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/EP2022/071862

Published:

- with international search report (Art. 21(3))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(22) International Filing Date:
03 August 2022 (03.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
21189699.8 04 August 2021 (04.08.2021) EP

(71) Applicants: **DOMPE' FARMACEUTICI SPA** [IT/IT];
VIA SANTA LUCIA 6, 20121 MILANO (IT). **ISTITUTO
NAZIONALE MALATTIE INFETTIVE LAZZARO
SPALLANZANI** [IT/IT]; Via Portuense 292, 00149 Roma
(IT).

(72) Inventors: **BECCARI, Andrea Rosario**; Via Tommaso
De Amicis, 95, 80131 Napoli NA (IT). **IACONIS, Daniela**;
Via Tommaso De Amicis 95, 80131 Napoli (IT). **TALARI-
CO, Carmine**; Via Tommaso De Amicis, 95, 80131 Napoli
NA (IT). **MANELFI, Candida**; Via Tommaso De Ami-
cis 95, 80131 Napoli NA (IT). **SCORZOLINI, Laura**; Via
Portuense, 292, oma RM, 00149 Roma (IT). **BORDI, Li-
cia**; Via Portuense, 292, 00149 Roma (IT). **MATUSALI,
Giulia**; Via Portuense, 292, 00149 Roma (IT). **NICASTRI,
Emanuele**; Via Portuense, 292, 00149 Roma (IT).

(74) Agent: **MAURI, Elisabetta Maria Ester**; c/o DOMPE'
FARMACEUTICI SPA, VIA SANTA LUCIA 6, 20121
MILANO (IT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE,
KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU,
LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: RALOXIFENE FOR USE IN THE TREATMENT OF SARS-COV-2 VARIANTS INFECTIONS

(57) Abstract: The present invention relates to Raloxifene or a pharmaceutically acceptable salt thereof for use in the treatment of an infection caused by one or more variants of SARS-CoV-2 in a subject.

WO 2023/012233 A1